PaxVax and Valneva team to market and distribute travel vaccines
Valneva's Cholarea vaccine DUKORAL will receive new markets in Italy, Spain and Portugal, while PaxVax's Vivotif will be available in Canada, Sweden, Norway and Denmark. This was made possible by both companies' recent expansions.
In February, Valneva gained access to a better distribution infrastructure after taking over SBL Vaccin Distribution. That's in addition to a company-owned Canadian infrastructure. PaxVax took a similar move when in Italy and Spain when it acquired Vivotif in July 2014.
"This agreement will complement Valneva's growing direct sales and marketing capabilities and enable the Company to leverage its sales and marketing team in the Nordics and Canada," Thomas Lingelbach, president and CEO and Franck Grimaud, deputy CEO of Valneva, said in a news release. "It will also ensure the availability of DUKORAL to people in the European countries who are travelling to regions of the world where cholera is endemic. We look forward to working with our new distribution partner to maintain a stable global supply and grow sales of both the DUKORAL and the Vivotif vaccines."